These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
291 related articles for article (PubMed ID: 25136089)
1. Vaccines against poverty. MacLennan CA; Saul A Proc Natl Acad Sci U S A; 2014 Aug; 111(34):12307-12. PubMed ID: 25136089 [TBL] [Abstract][Full Text] [Related]
2. New Vaccines for the World's Poorest People. Hotez PJ; Bottazzi ME; Strych U Annu Rev Med; 2016; 67():405-17. PubMed ID: 26356803 [TBL] [Abstract][Full Text] [Related]
3. Financial requirements of immunisation programmes in developing countries: a 2004-2014 perspective. Peny JM; Gleizes O; Covilard JP Vaccine; 2005 Aug; 23(37):4610-8. PubMed ID: 15979769 [TBL] [Abstract][Full Text] [Related]
4. Speeding Access to Vaccines and Medicines in Low- and Middle-Income Countries: A Case for Change and a Framework for Optimized Product Market Authorization. Ahonkhai V; Martins SF; Portet A; Lumpkin M; Hartman D PLoS One; 2016; 11(11):e0166515. PubMed ID: 27851831 [TBL] [Abstract][Full Text] [Related]
5. Vaccines for low-income countries. MacLennan CA Semin Immunol; 2013 Apr; 25(2):114-23. PubMed ID: 23757292 [TBL] [Abstract][Full Text] [Related]
6. A handful of 'antipoverty' vaccines exist for neglected diseases, but the world's poorest billion people need more. Hotez P Health Aff (Millwood); 2011 Jun; 30(6):1080-7. PubMed ID: 21653960 [TBL] [Abstract][Full Text] [Related]
7. New tendencies and strategies in international immunisation: GAVI and The Vaccine Fund. Martin JF; Marshall J Vaccine; 2003 Jan; 21(7-8):587-92. PubMed ID: 12531322 [TBL] [Abstract][Full Text] [Related]
8. The inception, achievements, and implications of the China GAVI Alliance Project on Hepatitis B Immunization. Kane MA; Hadler SC; Lee L; Shapiro CN; Cui F; Wang X; Kumar R Vaccine; 2013 Dec; 31 Suppl 9():J15-20. PubMed ID: 24331015 [TBL] [Abstract][Full Text] [Related]
12. European strategy for vaccine development against infectious diseases. Matthiessen L; Lång H; Klimathianaki M; Hanrahan F; Kerstiëns B; Martini A; Draghia-Akli R Vaccine; 2017 Jan; 35 Suppl 1():A20-A23. PubMed ID: 28017443 [TBL] [Abstract][Full Text] [Related]
13. Childhood vaccines and antibiotic use in low- and middle-income countries. Lewnard JA; Lo NC; Arinaminpathy N; Frost I; Laxminarayan R Nature; 2020 May; 581(7806):94-99. PubMed ID: 32376956 [TBL] [Abstract][Full Text] [Related]
14. Shaping markets to benefit global health - A 15-year history and lessons learned from the pentavalent vaccine market. Malhame M; Baker E; Gandhi G; Jones A; Kalpaxis P; Iqbal R; Momeni Y; Nguyen A Vaccine X; 2019 Aug; 2():100033. PubMed ID: 31384748 [TBL] [Abstract][Full Text] [Related]
15. Highly affordable vaccines are critical for our continued efforts to reduce global childhood mortality. Kaufmann SHE Hum Vaccin Immunother; 2019; 15(11):2660-2665. PubMed ID: 30973039 [TBL] [Abstract][Full Text] [Related]
16. Quality vaccines for all people: Report on the 16th annual general meeting of the Developing Countries Vaccine Manufacturers' Network, 05-07th October 2015, Bangkok, Thailand. Pagliusi S; Ting CC; Khomvilai S; Vaccine; 2016 Jun; 34(31):3562-7. PubMed ID: 26947496 [TBL] [Abstract][Full Text] [Related]
17. Costs of vaccine programs across 94 low- and middle-income countries. Portnoy A; Ozawa S; Grewal S; Norman BA; Rajgopal J; Gorham KM; Haidari LA; Brown ST; Lee BY Vaccine; 2015 May; 33 Suppl 1():A99-108. PubMed ID: 25919184 [TBL] [Abstract][Full Text] [Related]